PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2191 Views
-
Last post by NHE
-
- 0 Replies
- 1048 Views
-
Last post by NHE
-
- 0 Replies
- 10436 Views
-
Last post by NHE
-
- 0 Replies
- 2093 Views
-
Last post by Firidion
-
- 1 Replies
- 1360 Views
-
Last post by vesta
-
- 0 Replies
- 2096 Views
-
Last post by frodo
-
- 0 Replies
- 2016 Views
-
Last post by NHE
-
- 0 Replies
- 1520 Views
-
Last post by NHE
-
- 4 Replies
- 2515 Views
-
Last post by JohnC777